Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.

Authors

Naoki Izawa

St. Marianna University School of Medicine, Kawasaki, Japan

Naoki Izawa , Kohei Shitara , Toshiki Masuishi , Tadamichi Denda , Kentaro Yamazaki , Toshikazu Moriwaki , Hiroyuki Okuda , Chihiro Kondoh , Tomohiro Nishina , Akitaka Makiyama , Hideo Baba , Hironori Yamaguchi , Masato Nakamura , Yu Sunakawa , Kohei Akiyoshi , Mikio Sato , Kimio Yonesaka , Takayuki Yoshino , Takeharu Yamanaka , Kei Muro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

UMIN000031621

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 226)

Abstract #

226

Poster Bd #

Abstract Disclosures

FEATURED

Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.

Authors

Naoki Izawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

Abstract #

Poster Bd #

Similar Posters

Poster

Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial.

Poster

Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.

Poster

Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.

Poster

A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).